A rare liver disorder in a newborn became the testbed for the first in vivo CRISPR therapy, led by Berkeley’s Innovative ...

The global CRISPR gene editing market size is calculated at USD 4.77 billion in 2025 and is expected to reach around USD ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

In vivo base editing enables precise, single-nucleotide changes to DNA without double-strand breaks. A recent application in ...

UCD team uses novel polymer-based system to deliver corrective genes, an approach that appears to be better tolerated by ...

A man who was the first person in the UK to receive a groundbreaking gene-editing therapy on the NHS, said he felt " ...

The global biotechnology market is anticipated to surge to USD 1.78 trillion by 2034, driven by innovations in personalized ...

The FDA has granted rare pediatric disease designation to PBGENE-DMD, an experimental gene-editing therapy for Duchenne ...

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with genetic diseases?

A new gene therapy trial safely restores hearing in deaf children and adults, offering hope for those with DFNB9 deafness ...

Emerging oligonucleotides and gene editing therapies offer greater precision, long-term efficacy, and improved adherence in comparison to traditional statin therapies. This is especially true for ...

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, ...